RSS

breast cancer

Breast cancer treatment, eribulin (Halaven), will still be accessible to patients with advanced metastatic breast cancer despite recent guidance by the National Institute of Health and Care Excellence (NICE), according to Eisai. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The FDA has given the green light to an expansion of use of olaparib tablets (Lynparza) to now include the treatment of patients with certain types of breast cancer that have metastasized and whose tumours have a specific inherited genetic mutation. more

News

An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy drug for advanced breast cancer. more

News

Results from the PANACEA study, recently presented at the San Antonio Breast Cancer Symposium, have suggested that immunotherapy may help to overcome trastuzumab-resistant breast cancer. more

News

The US Food and Drug Administration (FDA) has approved the first biosimilar for the treatment of certain breast and stomach cancers, Ogivri (trastuzumab-dkst). more

News

Inflection Biosciences and the RCSI have entered into a research collaboration aiming to understand the mechanisms of resistance to major breast cancer therapies and examine potential new treatment for patients with a cancer that is unresponsive more

News

Two life-extending drugs will now be available to breast cancer patients on the NHS after price negotiations lead the National Institute for Health and Care Excellence (NICE) to approve them. more

News

The US FDA has approved Verzenio (abemaciclib), from Eli Lilly and Company, for the treatment of adult patients who have HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy. more

News

The Alliance Foundation Trials (AFT) — in conjunction with Pfizer and six international cancer research groups — has launched a randomised open-label Phase III clinical study, PATINA, to evaluate a combination therapy for breast cancer. more

News

An agreement has been formed by 3N Diagnostics and Fortress Diagnostics for the manufacture of the novel and patented breast cancer test, the Avisio FOXC1. more

Technology

The US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of the proposed biosimilar trastuzumab for the treatment of breast cancer. more

News

A researcher at Case Western Reserve University (CWRU) School of Medicine has been granted two awards from the National Institutes of Health (NIH) to develop nanotechnology drug delivery systems more

News

NHS England has struck a deal with Roche and endorsed by the National Institute for Health and Care Excellence (NICE) to make the breast cancer drug Kadcyla available for routine use on the NHS. more

News

World Cancer Research Fund International has released a new report that demonstrates an increased risk of breast cancer is associated with even moderate alcohol consumption. more

News

A diagnostic test for an aggressive form of breast cancer, basal-like breast cancer (BLBC), has obtained CE Marking. The Avisio FOXC1 immunohistochemistry (IHC) test is available from 3N Diagnostics (3NDx). more

Technology

Pfizer has announced it will provide its breast cancer drug, palbociclib — which has been provisionally rejected by NICE for routine use as a result of cost — to the NHS for free for up to five months until a final decision by NICE is made. more

News

NICE has updated its guidance surrounding the treatment of post-menopausal women with a family history of breast cancer, stating that they should be offered anastrozole. more

News

One in five women with breast cancer could benefit from existing treatments previously thought not to be effective. more

News

Scientists have identified a chemical compound that is highly effective at blocking the growth of breast cancer cells. more

News